References
  1. Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med,2015 ; 372(9): 835-845.
  2. Komatsu H, Tsunoda T, Inui A, Sogo T, Fujisawa T. Characteristics of hospitalized children infected with macrolide-resistant Mycoplasma pneumonia. Braz J Infect Dis, 2014 ; 18(3): 294-299.
  3. Izumikawa K. Clinical Features of Severe or Fatal Mycoplasma pneumoniae Pneumonia.Front Microbiol, 2016 ; 7: 800
  4. Yan C, Sun HM, Zhao HQ. Latest surveillance data on Mycoplasma pneumoniae infections in children, suggesting a new epidemic occurring in Beijing. J Clin Microbiol, 2016 ; 54: 1400-1401.
  5. Lee KY, Lee HS, Hong JH, et al . Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol, 2006 ; 41: 263-268.
  6. Li CC, Shang YX, Shen XZ, Chen ZM, Zhao XY. Guidelines for the management of community acquired pneumonia in children (revised in 2013).Chinese Journal of Pediatrics, 2013 ; (10): 745-752.
  7. Bajantri B, Venkatram S, Diaz-Fuentes G. Mycoplasma pneumoniae: a potentially severe infection. J Clin Med Res, 2018 ; 10: 535-544.
  8. Yan C, Xue GH, Zhao HQ, et al . Molecular and clinical characteristics of severe Mycoplasma pneumoniae pneumonia in children.Pediatr Pulmonol, 2019 ; 54(7): 1012-1021.
  9. Chan ED, Welsh CH. Fulminant Mycoplasma pneumoniae pneumonia.West J Med, 1995 ; 162(2): 133-142.
  10. Colom AJ, Teper AM. Post-infectious bronchiolitis obliterans.Pediatr Pulmonol, 2019 ; 54(2): 212-219
  11. Moonnumakal SP, Fan LL. Bronchiolitis obliterans in children.Curr Opin Pediatr, 2008 ; 20(3): 272-278.Table 1: General informations